Share This Article:

Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label, Uncontrolled and Non-Randomized Multicenter Observational Study

Abstract Full-Text HTML XML Download Download as PDF (Size:875KB) PP. 320-329
DOI: 10.4236/ojpsych.2015.54036    1,846 Downloads   2,244 Views  

ABSTRACT

Background: Fluvoxamine, a selective serotonin reuptake inhibitor is widely used in the treatment of depression, one of the most common disorders prevalent in Russia. However, studies demonstrating its efficacy and safety in routine settings in Russia are scarce. Methods: This prospective, uncontrolled, open-label study was conducted at 11 centers in Russia. Total 293 patients (aged ≥ 18 years), meeting DSM-IV criteria for depression and scoring ≥ 17 on 17-item Hamilton Rating Scale of Depression (HAMD-17) received fluvoxamine 50 - 300 mg for 6 weeks. Primary efficacy measures included change from baseline in the HAMD-17 and Clinical Global Impression (CGI) scores. Secondary efficacy measure was evaluation of sleep quality changes on HAMD-17 subscale. Safety was assessed by monitoring of adverse drug reactions (ADRs). Results: Mean age of patients was 42.7 years and the majority of them were women (72%). At the end of treatment (day 42), clinically significant reduction was observed in mean HAMD-17, CGI-severity of illness and HAMD-17 sleep sub-score from 23.1, 4.5 and 3.9 at baseline to day 42; change from baseline (Δ) was: Δ-17.3 [95% CI: -18.0; -16.7]), Δ-2.1 and Δ-3.4 [95% CI: -3.53; -3.20]), respectively. At day 42, 20.8% patients reported as normal (not at all ill) on the CGI-severity scale and 85% patients reported as “much improved” or “very much improved” on the CGI-change in severity and quality of life scores. Nausea (12.6%) and somnolence (5.1%) were the most frequently reported ADRs. No deaths or serious ADRs were reported but eight patients discontinued treatment due to ADRs. Conclusion: Treatment with fluvoxamine under routine settings showed marked improvement in Russian patients with depression as measured by HAMD-17 and CGI ratings and was thus efficacious as well as safe and well-tolerated.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Smulevich, A. , Ilyina, N. and Chitlova, V. (2015) Fluvoxamine in Treatment of Depression in Russian Patients: An Open-Label, Uncontrolled and Non-Randomized Multicenter Observational Study. Open Journal of Psychiatry, 5, 320-329. doi: 10.4236/ojpsych.2015.54036.

References

[1] World Health Organization. (2012) Depression a Global Public Health Concern.
http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf
[2] Lépine, J.P. and Briley, M. (2011) The Increasing Burden of Depression. Journal of Neuropsychiatric Disease and Treatment, 7, 3-7.
[3] Reddy, M.S. (2010) Depression: The Disorder and the Burden. Indian Journal of Psychological Medicine, 32, 1-2. http://dx.doi.org/10.4103/0253-7176.70510
[4] Pakriev, S., Kovalev, J. and Mozhaev, M. (2009) Prevalence of Depression in a General Hospital in Izhevsk, Russia. Nordic Journal of Psychiatry, 63, 469-474.
http://dx.doi.org/10.3109/08039480903062950
[5] Bobak, M., Pikhart, H., Pajak, A., Kubinova, R., Malyutina, S., Sebakova, H., et al. (2006) Depressive Symptoms in Urban Population Samples in Russia, Poland and the Czech Republic. The British Journal of Psychiatry, 188, 359-365. http://dx.doi.org/10.1192/bjp.188.4.359
[6] Nicholson, A., Pikhart, H., Pajak, A., Malyutina, S., Kubinova, R., Peasey, A., et al. (2008) Socio-economic Status over the Life-Course and Depressive Symptoms in Men and Women in Eastern Europe. Journal of Affective Disorders, 105, 125-136. http://dx.doi.org/10.1016/j.jad.2007.04.026
[7] Patel, D. (2008) Depression is the Most Common Mental Disorder in Community Settings, and Is a Major Cause of Disability. Occupational Medicine (London), 58, 453. http://dx.doi.org/10.1093/occmed/kqn135
[8] Gurovich, I.Y., Schmukler, A.B., Storozhakova, Y.A., Kiryanova, E.M., Salnikova, L.I., Gazha, A.K., et al. (2013) Depressive Symptoms Diagnosis and Treatment of Schizophrenia and Schizophrenia Spectrum Disorders in Russian Clinical Practice. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 113, 28-33.
[9] Smulevich, A.B., Drobizhev, M.A. and Ivanov, S.V. (2002) Schizophrenia and Schizophrenia Spectrum Disorders in General Hospital. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 102, 9-13.
[10] Smulevich, A.V. (2003) Depression and Schizophrenia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 103, 4-13.
[11] Kozyrev, V.N., Smulevich, A.B., Drobizhev, M.I., Kraeva, G.K. and Kubrakov, M.A. (2003) Psychotropic Drugs Used in a Psychiatric Hospital (Pharmaco-Epidemiologic Aspects). Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 103, 25-32.
[12] Gartlehner, G., Hansen, R.A., Thieda, P., De Veaugh-Geiss, A.M., Gaynes, B.N., Krebs, E.E., et al. (2007) Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Agency for Healthcare Research and Quality, Rockville.
http://www.effectivehealthcare.ahrq.gov/repFiles/Antidepressants_Final_Report.pdf13
[13] von Wolff, A., H?lzel, L.P., Westphal, A., H?rter, M. and Kriston, L. (2013) Selective Serotonin Reuptake Inhibitors and Tricyclic Antidepressants in the Acute Treatment of Chronic Depression and Dysthymia: A Systematic Review and Meta-Analysis. Journal of Affective Disorders, 144, 7-15.
http://dx.doi.org/10.1016/j.jad.2012.06.007
[14] National Institute for Health and Clinical Excellence (2009) Depression: The Treatment and Management of Depression in Adults (Update). National Clinical Practice Guideline 90.
http://www.nice.org.uk/nicemedia/pdf/CG90NICEguideline.pdf
[15] Hachisu, M. and Ichimaru, Y. (2000) Pharmacological and Clinical Aspects of Fluvoxamine (Depromel): The First Selective Serotonin Reuptake Inhibitor Approved for Clinical Use Employed in Japan. Folia Pharmacologica Japonica, 115, 271-279. http://dx.doi.org/10.1254/fpj.115.271
[16] Hrdina, P.D. (1991) Pharmacology of Serotonin Uptake Inhibitors: Focus on Fluvoxamine. Journal of Psychiatry & Neuroscience, 16, 10-18.
[17] Fabre, L., Birkhimer, L.J., Zaborny, B.A., Wong, L.F. and Kapik, B.M. (1996) Fluvoxamine versus Imipramine and Placebo: A Double-Blind Comparison in Depressed Patients. International Clinical Psychopharmacology, 11, 119-127.
[18] Kasper, S., M?ller, H.J., Montgomery, S.A. and Zondag, E. (1995) Antidepressant Efficacy in Relation to Item Analysis and Severity of Depression: A Placebo-Controlled Trial of Fluvoxamine versus Imipramine. International Clinical Psychopharmacology, 9, 3-12.
http://dx.doi.org/10.1097/00004850-199501004-00001
[19] Dalery, J. and Honig, A. (2003) Fluvoxamine versus Fluoxetine in Major Depressive Episode: A Double-Blind Randomized Comparison. Human Psychopharmacology, 18, 379-384.
http://dx.doi.org/10.1002/hup.490
[20] Westenberg, H.G. and Sandner, C. (2006) Tolerability and Safety of Fluvoxamine and Other Antidepressants. International Journal of Clinical Practice, 60, 482-491.
http://dx.doi.org/10.1111/j.1368-5031.2006.00865.x
[21] Panteleeva, G.P., Abramova, L.I. and Korenev, A.N. (2000) Selective Serotonin Reuptake Inhibitors in the Therapy of Various Types of Endogenous Depressions. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 100, 36-41.
[22] She?fer, M.S., Tsybina, M.I. and Davydenko, M.V. (2000) Fluvoxamine (Fevarin) in the Treatment of Depression. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 100, 64-67.
[23] Neznamov, G.G., Siuniakov, S.A., Teleshova, E.S., Dorofeeva, O.A., Chumakov, D.B. and Davydova, I.A. (2001) Therapeutic Action and Efficiency of Fevarin (Fluvoxamine) in Patients with Non-Psychotic Anxious and Apathic-Adynamic Depressions. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 101, 19-24.
[24] Averina, M., Nilssen, O., Brenn, T., Brox, J., Arkhipovsky, V.L. and Kalinin, A.G. (2005) Social and Lifestyle Determinants of Depression, Anxiety, Sleeping Disorders and Self-Evaluated Quality of Life in Russia—A Population-Based Study in Arkhangelsk. Social Psychiatry and Psychiatric Epidemiology, 40, 511-518. http://dx.doi.org/10.1007/s00127-005-0918-x
[25] Gafarov, V.V., Panov, D.O., Gromova, E.A., Gagulin, I.V. and Gafarova, A.V. (2013) The Influence of Depression on Risk Development of Acute Cardiovascular Diseases in the Female Population Aged 25 - 64 in Russia. International Journal of Circumpolar Health, 72. http://dx.doi.org/10.3402/ijch.v72i0.21223
[26] Sonawalla, S.B., Spillmann, M.K., Kolsky, A.R., Alpert, J.E., Nierenberg, A.A., Rosenbaum, J.F., et al. (1999) Efficacy of Fluvoxamine in the Treatment of Major Depression with Comorbid Anxiety Disorders. The Journal of Clinical Psychiatry, 60, 580-583. http://dx.doi.org/10.4088/JCP.v60n0903
[27] Furuse, T. and Hashimoto, K. (2009) Fluvoxamine Monotherapy for Psychotic Depression: The Potential Role of Sigma-1 Receptors. Annals of General Psychiatry, 8, 26. http://dx.doi.org/10.1186/1744-859x-8-26
[28] Kishimoto, A., Todani, A., Miura, J., Kitagaki, T. and Hashimoto, K. (2010) The Opposite Effects of Fluvoxamine and Sertraline in the Treatment of Psychotic Major Depression: A Case Report. Annals of General Psychiatry, 9, 23. http://dx.doi.org/10.1186/1744-859x-9-23
[29] Zohar, J., Keegstra, H. and Barrelet, L. (2003) Fluvoxamine as Effective as Clomipramine against Symptoms of Severe Depression: Results from a Multicentre, Double-Blind Study. Human Psychopharmacology, 18, 113-119. http://dx.doi.org/10.1002/hup.442
[30] Katoh, Y., Uchida, S., Kawai, M., Takei, N., Mori, N., Kawakami, J., et al. (2010) Onset of Clinical Effects and Plasma Concentration of Fluvoxamine in Japanese Patients. Biological & Pharmaceutical Bulletin, 33, 1999-2002. http://dx.doi.org/10.1248/bpb.33.1999
[31] Rapaport, M.H., Clary, C., Fayyad, R. and Endicott, J. (2005) Quality-of-Life Impairment in Depressive and Anxiety Disorders. American Journal of Psychiatry, 162, 1171-1178.
http://dx.doi.org/10.1176/appi.ajp.162.6.1171
[32] Stein, M., Fyer, A., Davidson, J., Pollack, M. and Wiita, B. (1999) Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry, 156, 756-760.
[33] Wilson, S.J., Bell, C., Coupland, N.J. and Nutt, D.J. (2000) Sleep Changes During Long-Term Treatment of Depression with Fluvoxamine—A Home-Based Study. Psychopharmacology, 149, 360-365.
http://dx.doi.org/10.1007/s002139900362
[34] Irons, J. (2005) Fluvoxamine in the Treatment of Anxiety Disorders. Neuropsychiatric Disease and Treatment, 1, 289-299.
[35] Horii, A., Uno, A., Kitahara, T., Mitani, K., Masumura, C., Kizawa, K., et al. (2007) Effects of Fluvoxamine on Anxiety, Depression, and Subjective Handicaps of Chronic Dizziness Patients with or without Neuro-Otologic Diseases. Journal of Vestibular Research, 17, 1-8.
[36] Omori, I.M., Watanabe, N., Nakagawa, A., Cipriani, A., Barbui, C., McGuire, H., et al. (2010) Fluvoxamine versus Other Anti-Depressive Agents for Depression. Cochrane Database of Systematic Reviews, 17, Article ID: CD006114. Malik, A.S., Boyko, O., Atkar, N. and Young, W.F. (2001) A Comparative Study of MR Imaging Profile of Titanium Pedicle Screws. Acta Radiologica, 42, 291-293.
http://dx.doi.org/10.1080/028418501127346846

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.